Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris Tokyo, September 21, 2019: …
Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate)…